ARCP-CCRA PRACTICE QUESTIONS EXAM AND PRACTICE EXAM NEWEST 2025/ 2026 TEST BANK| ARCP CCRA CERTIFICATION EXAM PREP WITH COMPLETE 550 REAL EXAM QUESTIONS AND CORRECT VERIFIED ANSWERS/ ALREADY GRADED A+ (BRAND NEW!!)

ARCP-CCRA PRACTICE QUESTIONS
EXAM AND PRACTICE EXAM NEWEST
2025/ 2026 TEST BANK| ARCP CCRA
CERTIFICATION EXAM PREP WITH
COMPLETE 550 REAL EXAM
QUESTIONS AND CORRECT VERIFIED
ANSWERS/ ALREADY GRADED A+
(BRAND NEW!!)
Duringmthemclinicalmtrial,mregulationsmrequiremthatmamsubjectmbemgivenmthemrightmto...



a.mTravel

b.mWithdrawmatmanymtime

c.mGetmfinancialmcompensation

d.mSpeakmtomamsponsor'smattorneym-mCORRECTmANSWERmc.mWithdrawmatmanymtime



WhichmsignaturesmaremrequiredmbymFDAmregulationmtombemonmthemconsentmform?



a.Theminvestigator

b.mThemsubject

c.mTheminvestigatormandmsubject

d.mThemsubjectmandmamwitnessm-mCORRECTmANSWERmb.mThemsubject



Whichmofmthemfollowingmstatementsmdescribesmanmadequatemandmwell-controlledmtrial?



a.mThemtrialmismcloselymmonitored

,b.mThemIPmmeetsmGMPmstandards

c.mThemeffectsmofmthemIPmcanmbemassessed

d.mSourcemdocumentationmismverifiedmformallmsubejctsm-
mCORRECTmANSWERmc.mThemeffectsmofmthemIPmcanmbemassessed




Whichmofmthemfollowingmrepresentsmwell-writtenminclusion/exclusionmcriteriamformanmanti-
hypertensivemprotocol?



1.msatisfactorymstressmtest

2.musemofmamHoltermmonitor

3.mnompreviousmhistorymofmstroke

4.mdiastolicmbloodmpressuremgreatermthanm100



a.m1mandm2monly

b.m1mandm3monly

c.m2mandm4monly

d.m3mandm4monlym-mCORRECTmANSWERmd.m3mandm4monly



Intent-to-treatmtrialmdatamanalysismonlymincludesmsubjectsmwhomwerem__________.



a.mscreened

b.mcompleted

c.mrandomized

d.mdiscontinuedm-mCORRECTmANSWERmc.mrandomized



Amtrialmprotocolmamendmentmismrequiredmifmtheremis:

, a.mamreplacementmofmamsite

b.mamsiteminvestigatormchange

c.manmincreaseminmthemsamplemsize

d.mammergerminvolvingmthemsponsorm-mCORRECTmANSWERmc.manmincreaseminmthemsamplemsize



Inmamdouble-
blindmtrialmcomparingmIPmAmtomIPmB,mthemtreatmentmwillmbemeithermq.d.mxm7mdaysmonmIPmAmormb.i.d.
mxm10mdaysmonmIPmBm(1:1).mThemcountriesmparticipatingmwillmbemthemUS,mCanada,mMexico,mandmthem


UK.mThemUSmhasmbeenmallocatedm2mtimesmmoremsubjectsmthanmeachmothermcountry.mThemtrialmnee
dsm2000msubjects,mandminmordermtommakemsuremtheremismamsufficientmsupply,mthemsponsormwillmadd
mamsupplymoveragemofm20%.mFormCanada,mhowmmanymcapsulesmofmeachmproductmwillmneedmtombem


producedmformthismtrial?



a.m1680mIP;m4800mIP

b.m3360mIP;m9600mIP

c.m2800mIP;m8000mIP

d.m8400mIP;m24,000mIPm-mCORRECTmANSWERma.m1680mIP;m4800mIP



WhenmchoosingmamCROmtommanagemamclinicalmtrial,mwhichmofmthemfollowingmaremrequiredmbymICHm
Guidelines?



1.mTransfermofmresponsibilitiesmmustmbemdocumentedminmwriting.

2.mResponsibilitiesmtransferredmtomthemCROmbecomemthemultimatemresponsibilitymofmthemCRO.

3.mAmsponsormmustmtransfermallmofmthemresponsibilitiesmtomonemCRO.

4.mObligationsmnotmdescribedminmanymwrittenmagreementmshallmbemdeemedmnotmtomhavemtransferr
ed.



a.m1mandm3monly